-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Practical Aspects of Building a New Immunotherapy Program: The Future of Cell Therapy

Program: Education Program
Session: The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
Hematology Disease Topics & Pathways:
Biological, antibodies, Therapies, CAR-Ts, immunotherapy, NK cells
Saturday, December 5, 2020, 1:55 PM-2:00 PM

Jesus G. Berdeja, MD

Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Disclosures: Berdeja: Genentech, Inc.: Research Funding; Bluebird: Research Funding; Karyopharm: Consultancy; Teva: Research Funding; Prothena: Consultancy; Poseida: Research Funding; Acetylon: Research Funding; Amgen: Consultancy, Research Funding; Abbvie: Research Funding; Vivolux: Research Funding; Constellation: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Kite Pharma: Consultancy; Cellularity: Research Funding; Legend: Consultancy; BMS: Consultancy, Research Funding; Kesios: Research Funding; CURIS: Research Funding; Novartis: Research Funding; Lilly: Research Funding; Janssen: Consultancy, Research Funding; Glenmark: Research Funding; Celgene: Consultancy, Research Funding; EMD Sorono: Research Funding; Servier: Consultancy; Bioclinica: Consultancy.

See more of: The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
See more of: Education Program
<< Previous Presentation | Next Presentation >>